CAPTRUST Financial Advisors
URGN icon

CAPTRUST Financial Advisors’s UroGen Pharma URGN Stock Holding History

CAPTRUST Financial Advisors’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-253
Closed -$2K – 5155
2022
Q1 		$2K Buy
253
+234
+1,232% +$1.82K ﹤0.01% 4547
2021
Q4 		$0 Buy
+19
New +$268 ﹤0.01% 4918

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

CAPTRUST Financial Advisors's URGN Position: Q2 2022 in Review

CAPTRUST Financial Advisors sold out of UroGen Pharma (URGN) in Q2 2022, closing a stake of 253 shares — an estimated $2K sold.

CAPTRUST Financial Advisors first reported a position in URGN in Q4 2021 and held it in 2 quarters. The position peaked at $2K in Q1 2022. 65 funds tracked by Wall St. Rank hold URGN as of Q2 2022.

  • CAPTRUST Financial Advisors reported no remaining UroGen Pharma position as of Q2 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 253 UroGen Pharma shares in Q2 2022, an estimated $2K.
  • CAPTRUST Financial Advisors first reported a position in UroGen Pharma in Q4 2021 and held it in 2 quarters.
  • CAPTRUST Financial Advisors's UroGen Pharma position peaked at $2K in Q1 2022.
  • 65 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2022, filed 16 Aug 2022.